Breaking News Instant updates and real-time market news.

JNJ

Johnson & Johnson

$138.10

-0.58 (-0.42%)

, ITCI

Intra-Cellular

$16.83

-0.38 (-2.21%)

12:25
10/23/18
10/23
12:25
10/23/18
12:25

JPMorgan pharma and biotech analysts to hold analyst/industry conference call

Smid Cap Biotech Analyst Fye, U.S. Major & Specialty Pharma Analyst Schott and Large Cap Biotech Analyst Kasiamov, along with Key Opinion Leader Dr. Aaronson, Clinical Research Director at the Sheppard Pratt Health System discuss the treatment landscape for biopolar depression and depressive disorders on an Analyst/Industry conference call to be held on October 23 at 1 pm.

JNJ

Johnson & Johnson

$138.10

-0.58 (-0.42%)

ITCI

Intra-Cellular

$16.83

-0.38 (-2.21%)

AGN

Allergan

$185.90

-1.85 (-0.99%)

SAGE

Sage Therapeutics

$118.28

0.25 (0.21%)

ALKS

Alkermes

$39.00

0.14 (0.36%)

ACAD

Acadia

$21.76

-0.01 (-0.05%)

  • 23

    Oct

  • 23

    Oct

  • 28

    Oct

  • 30

    Oct

  • 01

    Nov

  • 02

    Nov

  • 06

    Nov

  • 06

    Nov

  • 06

    Nov

  • 19

    Dec

  • 31

    Jan

JNJ Johnson & Johnson
$138.10

-0.58 (-0.42%)

10/17/18
WELS
10/17/18
NO CHANGE
Target $160
WELS
Outperform
Johnson & Johnson price target raised to $160 from $155 at Wells Fargo
Wells Fargo analyst Lawrence Biegelsen raised his price target for Johnson & Johnson to $160 from $155 following quarterly results. The analyst reiterates an Outperform rating on the shares.
10/16/18
PIPR
10/16/18
NO CHANGE
PIPR
Piper Jaffray discusses derivatives from J&J's Q3 results
Piper Jaffray analyst Matt O'Brien notes that Johnson & Johnson's (JNJ) global Medical Devices segment grew 1.7% organically in Q3, with sales of $6.6B falling $50M short of the consensus. The large joint segment continues to look relatively stable, with low-single-digit pricing pressures as expected, O'Brien tells investors in a research note. The analyst suspects Stryker (SYK) will continue to take share away from J&J and Zimmer Biomet (ZBH) in Q3. J&J's Spine segment was flat off of easy comps and after normalizing the Codman divestiture, the analyst adds. He continues to view J&J as a "share donor" to the pure-play spine names Globus Medical (GMED), NuVasive (NUVA) and SeaSpine (SPNE), with Globus' robot "continuing to provide share taking opportunities." Within Contact Lenses, J&J faced tough comps but reported a solid quarter in both the domestic and international markets, O'Brien says. He continues to see a "healthy" lens end market and one that is shifting to daily lenses from reusable, which he views as positive for Cooper Companies (COO). Further, the analyst notes that Diabetes continues to decelerate for J&J at a negative 20% clip given the Animas exit, which he thinks continues to be a positive for the pump names Insulet (PODD) and Tandem Diabetes (TNDM).
10/16/18
WELS
10/16/18
NO CHANGE
WELS
Drug price in ads not impactful, may cause confusion, says Wells Fargo
Wells Fargo analyst David Maris acknowledges that the U.S. Department of Health and Human Services' proposal to include drug prices in advertisements has a "noble goal" of making drugs more affordable and keeping patients well informed. However, given how different list prices are relative to out of pocket costs, "one must ask if this is increasing transparency or likely going to lead to more confusion," he contends. The analyst also believes that the unintended consequence could be worse care, while noting that the drug price information will likely fall into the category of the side effect information in drug ads currently, tuned out by many and will have no material impact. While he supports the idea of increased transparency, Maris wonders whether the potential benefit is not outweighed by the potential negative for the most vulnerable. Publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
10/05/18
SBSH
10/05/18
NO CHANGE
SBSH
Gilead may need Dicerna after Arrowhead, J&J deal, says Citi
Given the partnership announced yesterday between Arrowhead Pharmaceuticals (ARWR) and Johnson & Johnson (JNJ), Gilead Sciences' (GILD) hepatitis B virus portfolio may need another component and Dicerna Pharmaceuticals (DRNA) "could be one of them," Citi analyst Robyn Karnauskas tells investors in a research note. The analyst believes large pharma and Gilead are "still missing a key piece to bring a curative therapy to market that can rapidly and effectively lower HBsAg." The Arrowhead deal makes it apparent that HBV portfolios may need a multi-target approach and validates the RNAi platform to target HBV, the analyst contends.
ITCI Intra-Cellular
$16.83

-0.38 (-2.21%)

04/03/18
LEER
04/03/18
NO CHANGE
Target $25
LEER
Outperform
Intra-Cellular selloff on Alkermes news 'unwarranted,' says Leerink
Leerink analyst Geoffrey Porges notes that Alkermes (ALKS) announced a Refusal to File Letter from the FDA for ALKS-5461. ALKS-5461 is often linked with Intra-Cellular's (ITCI) lumateperone since both drugs are seeking approval in major psychiatric indications, and the analyst believes investors are considering the ALKS-5461 outcome as a proxy for the FDA's flexibility about approving lumateperone in 2019. However, Porges believes the "sympathy" selloff in Intra-Cellular, based on the Alkermes news, is "unwarranted" for several reasons, and does not believe the RTF letter for ALKS-5461 impacts the likelihood of the FDA's acceptance of the lumateperone NDA later this year, or lumateperone's approval in 2019. He reiterates an Outperform rating and $25 price target on Intra-Cellular's shares.
08/23/18
CANT
08/23/18
NO CHANGE
Target $32
CANT
Overweight
Intra-Cellular transferred with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Charles Duncan took over coverage of Intra-Cellular Therapies with an Overweight rating and $32 price target. The analyst sees a high probability of approval for lumateperone in schizophrenia.
04/02/18
CANT
04/02/18
NO CHANGE
Target $28
CANT
Overweight
Intra-Cellular weakness on ALKS 5642 news 'unsurprising,' says Cantor Fitzgerald
Cantor Fitzgerald analyst William Tanner reiterates an Overweight rating and $28 price target on Intra-Cellular (ITCI), but acknowledges that ALKS 5641-related weakness is "unsurprising" as Alkerme's (ALKS) drug and lumateperone "have been joined, somewhat, at the hip." The analyst believes lumateperone is not just about Schizophrenia and could be an important treatment for several neuropsychological disorders. Further, Tanner views the PDE-1 enzyme inhibitor ITI-214 as being an attractive drug candidate with potential to expand Intra-Cellular's footprint into other neurological disorders for which large unmet medical needs exist.
04/03/18
ADAM
04/03/18
NO CHANGE
Target $31
ADAM
Buy
Intra-Cellular weakness a buying opportunity, says Canaccord
Canaccord analyst Sumant Kulkarni noted Intra-Cellular (ITCI) sold off on the news the FDA issued a Refusal to File letter on Alkermes (ALKS) for its major depressive disorder drug candidate. The analyst views the pullback in Intra-Cellular as a buying opportunity heading into the mid-2018 potential filing of its own lumateperone drug for depression, as it is a more conventional design. Kulkarni reiterated his Buy rating and $31 price target on Intra-Cellular shares.
AGN Allergan
$185.90

-1.85 (-0.99%)

10/16/18
JMPS
10/16/18
NO CHANGE
Target $34
JMPS
Outperform
Aclaris Therapeutics price target lowered to $34 from $47 at JMP Securities
JMP Securities analyst Donald Ellis lowered his price target on Aclaris Therapeutics (ACRS) shares to $34 from $47 after the company announced a deal to acquire Rhofade from Allergan (AGN) and disclosed unaudited Q3 Eskata sales of about $0.5M, which missed his prior estimate of $2.8M. His lower price target is attributable to his updated Eskata estimates with the launch proceeding slower than expected, but Ellis maintains an Outperform rating on Aclaris shares, stating that he sees the Rhofade deal as "strategic and accretive."
10/18/18
WELS
10/18/18
NO CHANGE
WELS
Outperform
Allergan migraine update 'very positive' news, says Wells Fargo
Allergan yesterday announced the completion of two positive safety and tolerability studies for its oral anti-CGRP acute migraine treatment, ubrogepant, Wells Fargo analyst David Maris tells investors in a research note titled ": Effective? Check. Safe? Check. Oral Migraine Drug Clears Key Hurdle." The data showcase what Allergan has reiterated all along, that ubrogepant has shown to provide triptan-like efficacy in treating acute migraines with a lower adverse event profile and an absence of drug-induced elevated liver enzyme levels, Maris contends. The analyst, who currently models $175M in sales for ubrogepant in 2022, believes many on the Street are underestimating Allergan and ubrogepant "given the past concerns over hepatic safety that do not appear to be evident." Ubrogepant may have $1B-plus sales potential if approved, says Maris. He finds yesterday's safety update as "very positive" news for Allergan and keeps an Outperform rating on the stock.
10/18/18
MZHO
10/18/18
NO CHANGE
Target $210
MZHO
Buy
Allergan reported clean safety profile for migraine treatment, says Mizuho
Allergan yesterday reported a clean safety profile in two safety studies of ubrogepant for the treatment of acute migraine, Mizuho analyst Irina Koffler tells investors in a research note. The analyst believes these results may also de-risk atogepant, Allergan's second follow-on oral CGRP program in migraine prophylaxis. She reiterates a Buy rating on the shares with a $210 price target.
10/16/18
JEFF
10/16/18
NO CHANGE
Target $33
JEFF
Buy
Jefferies boosts Aclaris target to $33 on expected Rhofade accreation
Jefferies analyst David Steinberg raised his price target for Aclaris Therapeutics (ACRS) to $33 from $30 after the company acquired Rhofade from Allergan (AGN). As Allergan has already done much of the "heavy lifting" for the launch, and the product leverages Aclaris' current sales force, Rhofade should be accretive to EBITDA in Q4 of 2019, Steinberg tells investors in a research note. The analyst believes the drug is potentially a best in class product for skin condition rosacea. He thinks peak sales could conservatively reach $60M and keeps a Buy rating on Aclaris Therapeutics.
SAGE Sage Therapeutics
$118.28

0.25 (0.21%)

10/17/18
STFL
10/17/18
NO CHANGE
Target $239
STFL
Buy
Stifel confident in approval of Sage Therapeutics' brexanolone ahead of AdComm
Ahead of an FDA advisory committee meeting on Nov 2 to review brexanolone, Stifel analyst Paul Matteis said he is confident in FDA approval and expects the debate on the drug to be centered on labeling, REMS and necessary monitoring requirements. While noting that brexanolone comprises a minority of his Sage valuation, Matteis said the most important thing for the stock is that the panel is both positive and doesn't raise any sort of issue that would read negatively onto SAGE-217, which comprises the majority of his Sage valuation. He maintains a Buy rating and $239 price target on Sage Therapeutics shares.
08/07/18
PIPR
08/07/18
NO CHANGE
Target $206
PIPR
Overweight
Sage Therapeutics continues to make progress on Zulresso, says Piper Jaffray
Sage Therapeutics continues to make progress preparing for potential FDA approval/launch of Zulresso for post partum depression, Piper Jaffray analyst Danielle Brill tells investors in a research note following the company's Q2 results. The analyst expects the FDA panel on November 2 to be supportive of approval. She reiterates an Overweight rating on Sage shares with a $206 price target.
10/10/18
OPCO
10/10/18
INITIATION
Target $170
OPCO
Outperform
Sage Therapeutics initiated with an Outperform at Oppenheimer
Oppenheimer analyst Jay Olson started Sage Therapeutics with an Outperform rating and $170 price target. Sage should become a leader in anti-depressants with two drugs in late-stage development, IV brexanolone for postpartum depression and oral SAGE-217 for postpartum depression and major depressive disorder, Olson tells investors in a research note titled "Thyme to Buy SAGE." He believes the company's near-term catalysts are "skewed toward positive outcomes" and "could unlock significant value."
10/11/18
10/11/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Sage Therapeutics (SAGE) initiated with an Outperform at Oppenheimer. 2. Herbalife Nutrition (HLF) initiated with a Buy at Jefferies. 3. GreenSky (GSKY) initiated with a Buy at BTIG. 4. Nightstar Therapeutics (NITE) initiated with an Overweight at Cantor Fitzgerald. 5. KLX Energy (KLXE) initiated with a Buy at Gabelli. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
ALKS Alkermes
$39.00

0.14 (0.36%)

08/13/18
JEFF
08/13/18
NO CHANGE
Target $49
JEFF
Hold
Psychiatrists believe ALKS 3831 needs 50% treatment effect, says Jefferies
Jefferies analyst Biren Amin polled 25 psychiatrists who treat adult schizophrenia about Alkermes' ALKS 3831 and the upcoming Q4 readout for the Phase III Enlighten-2 trial evaluating the drug to olanzapine in patients with schizophrenia. Clinicians believe a 50% reduction in weight gain at six months would be clinically meaningful, but that this "may be a high bar," Amin tells investors in a research note. If Enlighten-2 shows less than a 50% reduction, price may play a key consideration in its adoption, the analyst adds. He currently models ALKS 3831 at peak sales of $500M. Amin has a Hold rating on Alkermes with a $49 price target.
08/06/18
STFL
08/06/18
INITIATION
STFL
Hold
Alkermes initiated with a Hold at Stifel
08/07/18
STFL
08/07/18
INITIATION
Target $45
STFL
Hold
Alkermes initiated with a Hold at Stifel
Stifel analyst Paul Matteis initiated coverage of Alkermes with a Hold rating and a $45 price target, stating that he has a more positive than consensus view on Aristada for schizophrenia and BIIB098 for Multiple Sclerosis, but a more cautious view on Vivitrol for addiction. While he is "cautiously optimistic" on ALKS3831 data in schizophrenia due in the fourth quarter, he is pessimistic on the odds of FDA approval for ALKS5461 for treatment-resistant depression without another positive clinical study, Matteis tells investors.
09/21/18
SBSH
09/21/18
NO CHANGE
SBSH
Buy
Alkermes risk/reward favorable into FDA panel meeting, says Citi
Citi analyst Liav Abraham believes expectations heading into November's FDA panel on Alkermes' depression drug are low, implying a favorable risk-reward heading into the event. While key opinion leaders have expressed concerns around ALKS 5461's "mixed" clinical data, they acknowledge the need for alternative therapeutic options in the adjunctive major depressive disorder space given, Abraham tells investors in a research note. The analyst sees reasons for the panel to vote either way ahead of the release of the briefing documents. She keeps a Buy rating on Alkermes.
ACAD Acadia
$21.76

-0.01 (-0.05%)

10/16/18
CANT
10/16/18
NO CHANGE
Target $27
CANT
Overweight
Acadia price target raised to $27 from $25 at Cantor Fitzgerald
Cantor Fitzgerald analyst Charles Duncan raised his price target for Acadia Pharmaceuticals to $27 and reiterates an Overweight rating on the shares. Acadia in August announced a licensing agreement with Neuren Pharmaceuticals for Trofinetide in Rett syndrome, Duncan tells investors in a research note. The analyst believes this is an underappreciated asset that could diversify the company's pipeline strategy over the next 12 months. After meeting with Neuren, Duncan has enhanced conviction on Trofinetide and believes that the path forward increases Phase 3 probability of success in the "as-yet untreatable neurodevelopmental disorder."
10/08/18
PIPR
10/08/18
NO CHANGE
Target $25
PIPR
Overweight
Piper a buyer of Acadia ahead of Nuplazid depression data
After reviewing available data for other agents that act as 5HT2AR antagonists, Piper Jaffray analyst Danielle Brill is "incrementally more optimistic" that Acadia Pharmaceuticals' Nuplazid will at least demonstrate a trend of efficacy in the ongoing Phase 2 Clarity trial in major depressive disorder. The current share price around $21 reflects only the base business in Parkinson's disease psychosis, Brill tells investors in a research note. She adds that her $25 price target for Acadia shares does not include any value for major depressive disorder. As such, the analyst believes downside is "likely marginal" on the Phase 2 data while upside could be anywhere from 30%-45%. Brill is a buyer of Acadia ahead of the data and reiterates an Overweight rating on the shares with a $25 price target.
09/21/18
09/21/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Under Armour (UA, UAA) upgraded to Neutral from Underweight at JPMorgan with analyst Matthew Boss saying he views the stock's risk/reward as more balanced following the recent underperformance. 2. Acadia (ACAD) upgraded to Overweight from Neutral at Piper Jaffray with analyst Danielle Brill citing the FDA announcement of maintained support for Nuplazid after its review. 3. AT&T (T) upgraded to Buy from Neutral at UBS with analyst John Hodulik saying the stock is trading near all-time low valuations, and at its widest valuation gap to Verizon (VZ), given a mix of EBITDA declines, concerns over the debt load and secular issues impacting the space. 4. Diamond Offshore (DO) upgraded to Buy from Hold at HSBC. 5. Ingersoll-Rand (IR) upgraded to Overweight from Neutral at JPMorgan with analyst Stephen Tusa saying he views the stock's discounted valuation relative to peers as unwarranted following the company's transformation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/21/18
HCWC
09/21/18
NO CHANGE
Target $60
HCWC
Buy
Acadia shares should normalize after FDA safety clearance, says H.C. Wainwright
H.C. Wainwright analyst Andrew Fein said the FDA announcement of its conclusion that no new or unexpected safety risks associated with Nuplazid were identified eliminates the worse case scenario for Acadia and he believes the stock should normalize following the FDA safety clearance. He expects a gradual reversal of the negative impact on sales that had been prompted by the CNN report and sees additional indications having the potential to "markedly expand" Nuplazid's commercial upside. Fein reiterates a Buy rating and $60 price target on Acadia shares.

TODAY'S FREE FLY STORIES

HYMTF

Hyundai Motor

$0.00

(0.00%)

21:09
03/21/19
03/21
21:09
03/21/19
21:09
Periodicals
Breaking Periodicals news story on Hyundai Motor »

Elliott Management loses…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SMTS

Sierra Metals

$1.64

0.05 (3.14%)

21:01
03/21/19
03/21
21:01
03/21/19
21:01
Hot Stocks
Sierra Metals announces 66% of Yauricocha Mine workers waged illegal strike »

Sierra Metals announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Mar

LGF.B

Lionsgate

$15.17

0.4 (2.71%)

, NFLX

Netflix

$378.09

2.94 (0.78%)

20:32
03/21/19
03/21
20:32
03/21/19
20:32
Recommendations
Lionsgate, Netflix, Apple, Spotify, Roku analyst commentary at SunTrust »

Apple event may be…

LGF.B

Lionsgate

$15.17

0.4 (2.71%)

NFLX

Netflix

$378.09

2.94 (0.78%)

AAPL

Apple

$195.07

6.93 (3.68%)

SPOT

Spotify

$144.04

-0.01 (-0.01%)

ROKU

Roku

$66.82

1.86 (2.86%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

TSLA

Tesla

$274.10

0.6 (0.22%)

20:13
03/21/19
03/21
20:13
03/21/19
20:13
Hot Stocks
End of Tesla's referral program reduced costs, allowed to pass on savings »

In its blog, Tesla…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HSBC

HSBC

$41.07

-0.16 (-0.39%)

, BLK

BlackRock

$430.32

0.35 (0.08%)

19:44
03/21/19
03/21
19:44
03/21/19
19:44
Periodicals
Breaking Periodicals news story on HSBC, BlackRock »

HSBC reaches deal to use…

HSBC

HSBC

$41.07

-0.16 (-0.39%)

BLK

BlackRock

$430.32

0.35 (0.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

UBER

Uber

$0.00

(0.00%)

, ICE

IntercontinentalExchange

$73.36

0.15 (0.20%)

19:21
03/21/19
03/21
19:21
03/21/19
19:21
Periodicals
Uber selects NYSE for 2019 IPO, Bloomberg reports »

Uber (UBER) has picked…

UBER

Uber

$0.00

(0.00%)

ICE

IntercontinentalExchange

$73.36

0.15 (0.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 17

    May

  • 28

    May

PIN

Pinterest

$25.63

-0.07 (-0.27%)

19:18
03/21/19
03/21
19:18
03/21/19
19:18
Periodicals
Pinterest moves up IPO timing, seeks to list shares on NYSE in April, WSJ says »

Pinterest has moved up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TAP

Molson Coors

$60.80

1.04 (1.74%)

, BUD

AB InBev

$83.94

0.52 (0.62%)

18:57
03/21/19
03/21
18:57
03/21/19
18:57
Periodicals
MillerCoors sues AB InBev over corn syrup claims, WSJ reports »

MillerCoors, a subsidiary…

TAP

Molson Coors

$60.80

1.04 (1.74%)

BUD

AB InBev

$83.94

0.52 (0.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    May

OSS

One Stop Systems

$2.52

(0.00%)

, AMRN

Amarin

$18.77

-0.24 (-1.26%)

18:40
03/21/19
03/21
18:40
03/21/19
18:40
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: One…

OSS

One Stop Systems

$2.52

(0.00%)

AMRN

Amarin

$18.77

-0.24 (-1.26%)

GME

GameStop

$10.54

0.06 (0.57%)

DLNG

Dynagas LNG

$2.61

0.025 (0.97%)

ZUO

Zuora

$24.34

0.62 (2.61%)

CAL

Caleres

$25.75

-0.08 (-0.31%)

OPNT

Opiant Pharmaceuticals

$14.00

0.5 (3.70%)

NKE

Nike

$88.05

1.3597 (1.57%)

CTAS

Cintas

$208.00

2.78 (1.35%)

CNAT

Conatus

$2.91

0.02 (0.69%)

GG

Goldcorp

$11.17

0.13 (1.18%)

NEM

Newmont Mining

$34.32

0.44 (1.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Mar

  • 21

    Mar

  • 21

    Mar

  • 21

    Mar

  • 21

    Mar

  • 21

    Mar

  • 22

    Mar

  • 25

    Mar

  • 02

    Apr

  • 04

    Apr

  • 04

    Apr

  • 11

    Apr

  • 16

    Apr

  • 23

    Apr

UBER

Uber

$0.00

(0.00%)

, ICE

IntercontinentalExchange

$73.36

0.15 (0.20%)

18:40
03/21/19
03/21
18:40
03/21/19
18:40
Periodicals
Uber selects NYSE for 2019 IPO, Bloomberg reports »

Uber (UBER) has picked…

UBER

Uber

$0.00

(0.00%)

ICE

IntercontinentalExchange

$73.36

0.15 (0.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 17

    May

  • 28

    May

CVS

CVS Health

$57.40

1.23 (2.19%)

18:34
03/21/19
03/21
18:34
03/21/19
18:34
Hot Stocks
CVS Health CEO: Off to great start with Aetna integration »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$284.63

3.19 (1.13%)

18:30
03/21/19
03/21
18:30
03/21/19
18:30
Periodicals
EU to offer U.K. Brexit negotiating period extension, Reuters says »

The EU plans to grant the…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$284.63

3.19 (1.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NOK

Nokia

$6.26

-0.03 (-0.48%)

18:20
03/21/19
03/21
18:20
03/21/19
18:20
Periodicals
Nokia not planning to take on new business in Iran in 2019, Reuters says »

Nokia said it does not…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    May

DNR

Denbury Resources

$1.95

0.06 (3.17%)

, PVAC

Penn Virginia

$54.29

1.74 (3.31%)

18:17
03/21/19
03/21
18:17
03/21/19
18:17
Hot Stocks
Denbury Resources: Penn Virginia deal was unlikely to receive majority approval »

Chris Kendall,…

DNR

Denbury Resources

$1.95

0.06 (3.17%)

PVAC

Penn Virginia

$54.29

1.74 (3.31%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    May

IMMP

Immutep

$2.40

-0.095 (-3.82%)

18:11
03/21/19
03/21
18:11
03/21/19
18:11
Hot Stocks
Immutep announces U.S. patent for Eftilagimod Alpha in cancer »

Immutep Limited is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PVAC

Penn Virginia

$54.29

1.74 (3.31%)

, DNR

Denbury Resources

$1.95

0.06 (3.17%)

18:08
03/21/19
03/21
18:08
03/21/19
18:08
Hot Stocks
Penn Virginia, Denbury Resources mutually agree to terminate merger pact »

Penn Virginia (PVAC)…

PVAC

Penn Virginia

$54.29

1.74 (3.31%)

DNR

Denbury Resources

$1.95

0.06 (3.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    May

LLL

L3 Technologies

$208.75

1.535 (0.74%)

17:44
03/21/19
03/21
17:44
03/21/19
17:44
Hot Stocks
L3 Technologies awarded $131.78M Air Force contract »

L3 Technologies has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Apr

  • 01

    May

GM

General Motors

$37.35

0.35 (0.95%)

17:42
03/21/19
03/21
17:42
03/21/19
17:42
Periodicals
GM to invest $300M in Orion EV/AV factory, Reuters reports »

General Motors intends to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Mar

  • 30

    Apr

GD

General Dynamics

$169.81

1.21 (0.72%)

17:42
03/21/19
03/21
17:42
03/21/19
17:42
Hot Stocks
General Dynamics awarded $465.15M Navy contract for CVN shipyard availabilities »

General Dynamics has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

NKE

Nike

$88.05

1.3597 (1.57%)

17:41
03/21/19
03/21
17:41
03/21/19
17:41
Earnings
Breaking Earnings news story on Nike »

Nike sees FY20 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Mar

  • 04

    Apr

  • 04

    Apr

NKE

Nike

$88.05

1.3597 (1.57%)

17:39
03/21/19
03/21
17:39
03/21/19
17:39
Earnings
Nike sees Q4 revenue growth in high single-digit range, consensus $10.38B »

Sees Q4 gross margin…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Mar

  • 04

    Apr

  • 04

    Apr

NKE

Nike

$88.05

1.3597 (1.57%)

17:36
03/21/19
03/21
17:36
03/21/19
17:36
Hot Stocks
Nike says it is not taking China momentum for granted »

Says leveraging the power…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Mar

  • 04

    Apr

  • 04

    Apr

LOV

Spark Networks

$11.29

(0.00%)

17:34
03/21/19
03/21
17:34
03/21/19
17:34
Hot Stocks
Spark Networks to acquire Zoosk, sees adjusted EBITDA to exceed $50M in 2020 »

Spark Networks announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACA

Arcosa

$29.74

-0.16 (-0.54%)

17:29
03/21/19
03/21
17:29
03/21/19
17:29
Initiation
Arcosa initiated at DA Davidson »

Arcosa initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$138.09

0.86 (0.63%)

17:24
03/21/19
03/21
17:24
03/21/19
17:24
Hot Stocks
Johnson & Johnson sees Q1 charge of about $700M related to AL-8176 »

On March 21, Johnson…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Apr

  • 25

    Apr

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.